Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Estrella Immunopharma, Inc. (ESLA) had Income from Continuous Operations of $-2.31M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-2.31M |
|
-- |
|
-- |
|
$2.08M |
|
$-2.08M |
|
$-0.22M |
|
$-2.31M |
|
$-2.31M |
|
$-2.31M |
|
|
Income from Continuous Operations |
$-2.31M |
$-2.31M |
|
$-2.31M |
|
$-2.08M |
|
$-2.08M |
|
43.00M |
|
43.00M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$1.82M |
|
-- |
|
-- |
|
$1.82M |
|
$9.26M |
|
-- |
|
-- |
|
$9.26M |
|
$-7.43M |
|
$-7.43M |
|
$-7.43M |
|
43.03M |
|
| Cash Flow Statement Financials | |
$-8.48M |
|
-- |
|
$7.24M |
|
$1.38M |
|
$0.15M |
|
$-1.24M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
31.04% |
|
31.04% |
|
-126.40% |
|
31.04% |
|
$-0.17 |
|
$-0.20 |
|
$-0.20 |
|